Plerixafor (mozobil)

DRUG3 trials

Sponsors

University Health Network, Toronto, Stephen Couban, Masonic Cancer Center, University of Minnesota

Conditions

Acute Myeloid LeukemiaGraft FailureHemoglobinopathiesMalignant Lymphoma, Stem Cell TypeSickle Cell Disease

Phase 2

Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor

CompletedNCT01403896

Stephen CoubanMalignant Lymphoma, Stem Cell Type

Start: 2012-04-30End: 2015-12-31Updated: 2017-08-02

Allo HSCT for High Risk Hemoglobinopathies

RecruitingNCT06872333

Masonic Cancer Center, University of MinnesotaGraft Failure, Hemoglobinopathies, Sickle Cell Disease

Start: 2024-11-19End: 2032-06-01Target: 62Updated: 2026-06-04

Unknown Phase

Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection

CompletedNCT01141543

University Health Network, TorontoAcute Myeloid Leukemia

Start: 2010-05-31End: 2014-05-31Updated: 2014-07-18

Related Papers

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability

Biology of Blood and Marrow Transplantation2019-01-1419 citations